Physician profile
Arnon E Rubin
NPI 1245217413
$10,419.05
in general payments reported to CMS, 2019-2025
25 companies · $506 in 2025
The $506 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,430 · 2020: $2,928 · 2021: $82.84 · 2022: $186 · 2023: $462 · 2024: $824 · 2025: $506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,428 · Education: $215 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,427.68 |
| Education | $214.72 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $6,105.00 | 2019-2025 | Nucala, Trelegy Ellipta |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Mylan Specialty L.P. | $746.62 | 2020-2024 | Yupelri |
| Jazz Pharmaceuticals INC. | $663.13 | 2020-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $269.25 | 2023-2024 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $210.77 | 2019-2025 | Ofev, Jascayd |
| Merck Sharp & Dohme LLC | $81.32 | 2023-2025 | Zerbaxa, Dificid |
| Astrazeneca Pharmaceuticals Lp | $70.63 | 2020-2025 | Airsupra |
| Ceribell, INC. | $67.14 | 2024 | Pocket Eeg Device |
| Harmony Biosciences LLC | $60.40 | 2023 | Wakix |
| Grifols USA, LLC | $54.60 | 2024 | Prolastin-C Liquid |
| Genentech USA, INC. | $52.63 | 2019 | |
| Insmed, INC. | $52.17 | 2024-2025 | Arikayce, Brinsupri |
| Tactile Systems Technology INC | $51.08 | 2023-2025 | Flexitouch Plus, Nimbl, Entre Plus |
| Vifor Pharma, INC. | $46.80 | 2025 | Veltassa, Zemaira |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $45.69 | 2019 | |
| Electromed, INC. | $42.34 | 2025 | Smartvest |
| Vapotherm INC | $32.84 | 2021 | |
| Gilead Sciences, INC. | $32.06 | 2024 | Veklury |
| Inspire Medical Systems, INC. | $25.59 | 2025 | Inspire |
| Philips North America LLC | $24.99 | 2025 | Vest Therapy Und |
| Takeda Pharmaceuticals U.S.A., INC. | $23.57 | 2024 | Glassia |
| Inogen, INC. | $22.40 | 2025 | |
| Lilly USA, LLC | $19.25 | 2025 | Zepbound |
| Pfizer INC. | $18.78 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnon Rubin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.